Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Expenses data on record, last reported at $5.0 million in Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 13.76% to $5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.0 million, a 13.76% increase, with the full-year FY2025 number at $9.1 million, up 17.65% from a year prior.
  • Accumulated Expenses reached $5.0 million in Q1 2026 per FULC's latest filing, down from $9.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for FULC hit a ceiling of $12.5 million in Q2 2022 and a floor of $2.3 million in Q1 2024.
  • A 5-year average of $5.3 million and a median of $4.4 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 532.35% in 2022, then plummeted 67.84% in 2024.
  • Tracing FULC's Accumulated Expenses over 5 years: stood at $4.2 million in 2022, then rose by 11.9% to $4.7 million in 2023, then skyrocketed by 63.29% to $7.7 million in 2024, then rose by 17.65% to $9.1 million in 2025, then plummeted by 45.28% to $5.0 million in 2026.
  • Business Quant data shows Accumulated Expenses for FULC at $5.0 million in Q1 2026, $9.1 million in Q4 2025, and $2.8 million in Q3 2025.